• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Page 3 > News & stories

Statements

Page 3 > News & stories

Statements

filters

Type & Disease
Topic
Location
Date Range
Type & Disease

By Type

news type

By Disease

diseases

Topic

By Topic

topic type

Location

By Location

location-news

Date Range

By Year

date range filter – slider
1999 — 2026

Results

No results found. Please try using different filter option(s).

Global Health Now
In the media
27 May 2026

The Long, Strange Journey of Mycetoma Research

Global Health Now
Scientific articles
14 May 2026

In vitro profiling of Trypanosoma cruzi inhibitors identified from high throughput screening and application to parasite painting

International Journal for Parasitology: Drugs and Drug Resistance
Statements
19 May 2026

DNDi interventions at the 79th World Health Assembly

Dr Sergio Sosa-Estani
Statements
15 May 2026

DNDi statement on hantavirus outbreak: ‘Investment in pandemic preparedness efforts remains insufficient.’

Scientific articles
13 May 2026

Chemical genetics reveals Leishmania KKT2 and CRK9 kinase activity is required for cell cycle progression

PLOS Pathogens
Statements
13 May 2026

DNDi’s briefing note for 79th World Health Assembly

Close up of legs with sandals on a dry soil
Press releases
12 May 2026

DNDi welcomes GHIT support for global evaluation and registration of fosravuconazole for eumycetoma, in collaboration with Eisai

Thai Rath logo
In the media
29 Apr 2026

Thailand approves ravidasvir, a new drug for hepatitis C, increasing chances of complete cure

Thai Rath
Scientific articles
14 May 2026

Mycetoma as a major cause of limb amputation in Northeastern Ethiopia: A facility-based retrospective study

PLOS Neglected Tropical Diseases
Nature Africa logo
In the media
6 May 2026

Fourteen days to recovery from kala-azar

Nature Africa
Scientific articles
30 Apr 2026

Overcoming Trypanosoma cruzi persistence with a mechanistically distinct drug combination

npj Antimicrobials and Resistance
Thai Rath logo
In the media
29 Apr 2026

ไทยรับรอง “ราวิดาสเวียร์” ยาใหม่รักษาไวรัสตับอักเสบซี เพิ่มโอกาสรักษาหายขาด

Thai Rath
Press releases
27 Apr 2026

Thailand registers ravidasvir, a simple-to-use and effective antiviral for hepatitis C, expanding treatment options for Thai patients

Alma Preta logo
In the media
25 Apr 2026

‘Estamos na fase de eliminação’: RD Congo avança no combate à doença que matou milhões na África

Alma Preta
Times of India logo
In the media
24 Apr 2026

Dengue treatments in 2-3 years, but cases set to rise with climate change

Times of India
The New Indian Express logo
In the media
23 Apr 2026

India eyes dengue treatment rollout within five years as vaccine pipeline advances

The New Indian Express
loading
Loading...
Statements
28 Feb 2023

DNDi’s submission to the Technical Assessment component of the first Global Stocktake

Statements
22 Feb 2023

DNDi comments on the zero draft of the WHO CA+ for consideration of the Intergovernmental Negotiating Body at INB4 & 5

Statements
1 Feb 2023

DNDi interventions at the 152nd session of the WHO Executive Board

Statements
2 Dec 2022

DNDi‘s comments on the conceptual zero draft for the consideration of the Intergovernmental Negotiating Body at INB3

Statements
14 Nov 2022

DNDi’s response to the Public consultation related to the WHA 75.8

Statements
29 Sep 2022

DNDi intervention at the Intergovernmental Negotiating Body second round of public hearings

Statements
18 Jul 2022

DNDi‘s comments on the working draft of the WHO CAll for the consideration of the INB at its second meeting

Statements
23 Jun 2022

DNDi Executive Director Dr Bernard Pécoul’s address to the Kigali Summit on Malaria and NTDs

Statements
16 Jun 2022

DNDi written comments on the Intergovernmental Negotiating Body White Paper

Statements
15 Jun 2022

DNDi endorses consensus statement on gender-responsive international instrument for pandemic prevention, preparedness, and response

Statements
24 May 2022

DNDi interventions at the 75th World Health Assembly

Statements
18 Apr 2022

DNDi‘s initial comments on the Intergovernmental Negotiating Body deliberations

Statements
12 Apr 2022

DNDi intervention at the Intergovernmental Negotiating Body first round of public hearings

Statements
1 Feb 2022

DNDi briefing note for the 150th session of the WHO Executive Board

Statements
30 Jan 2022

Open letter to WHO on the urgent need for COVID-19 self-testing for LMICs

Statements
27 Jan 2022

Research funding shortfalls threaten progress for neglected patients

1 2 … 5 ›

Connect and share

Follow us on social media to stay updated and help us share the stories of neglected patients.  

Linkedin Instagram X-twitter Facebook Youtube
EM PORTUGUÊS
EN ESPAÑOL
Linkedin-in Instagram Youtube X-twitter Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license